ConductScience.org, home

Paper6797571

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.

Smith IE and 10 others. Br Med J (Clin Res Ed), 1981. Cited by 156 papers, by iCite.

Cite this record

ConductScience Library. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Papers, record 6797571. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6797571

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
PubMed
Journal
Br Med J (Clin Res Ed)
PubMed
Year
1981
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
156
iCite
Relative citation ratio, by iCite
5.19
iCite
Revised in PubMed
2019-05-01
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Smith IEI E
2Harris ALA L
3Morgan MM
4Ford HTH T
5Gazet JCJ C
6Harmer CLC L
7White HH
8Parsons CAC A
9Villardo AA
10Walsh GG
11McKinna JAJ A

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AminoglutethimideMajor topic
Breast NeoplasmsMajor topic
TamoxifenMajor topic
Adult
Aged
Bone Neoplasms
Clinical Trials as Topic
Drug Resistance
Female
Humans
Male
Menopause
Middle Aged
Random Allocation

Source PubMed

Download CSV of topics

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14292247Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.J Clin Endocrinol Metab1967https://conductscience.org/library/papers/4292247PubMed
2856236Assessment of response to therapy in advanced breast cancer.Br J Cancer1977https://conductscience.org/library/papers/856236PubMed
36249490The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.Cancer1980https://conductscience.org/library/papers/6249490PubMed
4365330Tamoxifen in advanced breast cancer.Cancer Treat Rev1978https://conductscience.org/library/papers/365330PubMed
5446416Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide.Endocrinology1979https://conductscience.org/library/papers/446416PubMed
680576Aminoglutethimide in treatment of metastatic breast carcinoma.Lancet1978https://conductscience.org/library/papers/80576PubMed

Download CSV of references

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 156 citations.

PMIDTitleJournalYearIn PapersSource
39821038Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.Adv Exp Med Biol2025https://conductscience.org/library/papers/39821038PubMed
38188305Aromatase inhibitors: the journey from the state of the art to clinical open questions.Front Oncol2023https://conductscience.org/library/papers/38188305PubMed
34801042Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study.Radiat Oncol2021https://conductscience.org/library/papers/34801042PubMed
26969590The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Horm Cancer2016https://conductscience.org/library/papers/26969590PubMed
22317766The sequential use of endocrine treatment for advanced breast cancer: where are we?Ann Oncol2012https://conductscience.org/library/papers/22317766PubMed
20616198The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.Ann Oncol2011https://conductscience.org/library/papers/20616198PubMed
17973095Aromatase inhibitors: past, present and future in breast cancer therapy.Med Oncol2008https://conductscience.org/library/papers/17973095PubMed
17333340Letrozole in advanced breast cancer: the PO25 trial.Breast Cancer Res Treat2007https://conductscience.org/library/papers/17333340PubMed
12038879Aromatase inhibitors and inactivators for breast cancer therapy.Drugs Aging2002https://conductscience.org/library/papers/12038879PubMed
10146895Systemic therapy in breast cancer: efficacy and cost utility.Pharmacoeconomics1994https://conductscience.org/library/papers/10146895PubMed
9279502Breast cancer therapies in development. A review of their pharmacology and clinical potential.Drugs1997https://conductscience.org/library/papers/9279502PubMed
8595151Aromatase inhibitors--where are we now?Br J Cancer1996https://conductscience.org/library/papers/8595151PubMed
8554983Oestrogen receptor: a stable phenotype in breast cancer.Br J Cancer1996https://conductscience.org/library/papers/8554983PubMed
8477145Postmenopausal breast cancer. Drug therapy in the 1990s.Drugs Aging1993https://conductscience.org/library/papers/8477145PubMed
8260359cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo.Br J Cancer1993https://conductscience.org/library/papers/8260359PubMed
7981453The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.Breast Cancer Res Treat1994https://conductscience.org/library/papers/7981453PubMed
7949205First generation aromatase inhibitors--aminoglutethimide and testololactone.Breast Cancer Res Treat1994https://conductscience.org/library/papers/7949205PubMed
7797604Formestane: an effective first-line endocrine treatment for advanced breast cancer.J Cancer Res Clin Oncol1995https://conductscience.org/library/papers/7797604PubMed
6871483Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.Breast Cancer Res Treat1983https://conductscience.org/library/papers/6871483PubMed
6861259Trilostane in the treatment of advanced breast cancer.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6861259PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6797571

GET https://conductscience.org/api/papers/v1/6797571/cited_by?page=2